Meiragtx Holdings Plc (MGTX) Stock Price, Quote & News

Company Profile

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 860 7985

Website: meiragtx.com

Address:

655 Third Avenue, Suite 1115, New York, United States

CandleCloser Feb. 4 at 3:52 PM

$MGTX is a clinical-stage biotech (MeiraGTx) developing gene therapies for inherited diseases; its pipeline is promising but carries the high technical and regulatory risks of gene therapy.

1 · Reply

vu_jade Feb. 3 at 5:18 PM

$MGTX decent little news announcement today .. Chart turning more positive

0 · Reply

ErnieWorthing84 Feb. 3 at 5:17 PM

$MGTX Looks like they’re advancing the undisclosed dry AMD indication on Corp deck

0 · Reply

vu_jade Feb. 3 at 3:37 PM

$MGTX looking more Bullish here … needs some News

0 · Reply

DARKP00L Feb. 3 at 1:21 PM

$MGTX 08:18 on Feb. 03 2026 ZipBio Disclosed An Exclusive License Agreement With MeiraGTx, As Per Which MeiraGTx Will Receive Exclusive Rights To ZipBio's First-In-Class Therapies For Geographic Atrophy, Targeting The Complement Pathway #tradeideas

0 · Reply

AimSmall Feb. 2 at 5:13 PM

$MGTX https://substack.com/@aimsmall/p-186344002

1 · Reply

slinghook67 Jan. 31 at 5:05 PM

$MGTX This is worth a listen as Pankaj's insights are very informative. Through his Venture fund (2468), he's one of the original investors in Hologen. While he doesn't mention Hologen specifically, he talks extensively about Healthcare and it's potential specific to AI and how important it is to "go for homeruns" and always "bet on the jockey." The context of both of those references, and the linkage to Hologen and MeiraGTx, will make perfect sense when you listen to the full interview. https://youtu.be/c4TUGXGE2KQ?si=RXSDq4qQZSrDlCxk

1 · Reply

slinghook67 Jan. 30 at 3:13 AM

$MGTX This might as well have been written for MeiraGTx.... It's dead on. https://www.bain.com/insights/pharmaceuticals-m-and-a-report-2026/

1 · Reply

OptionsTag_902 Jan. 29 at 7:41 PM

$MGTX Quietly consolidating, watch for a breakout if volume confirms

0 · Reply

slinghook67 Jan. 29 at 12:17 PM

$MGTX Wow... an absolute MUST read.... https://www.statnews.com/2026/01/28/hologen-ai-biotech-startup-series-a-fundraise/

4 · Reply

ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy

Nov 20, 2025, 3:00 PM EST - 2 months ago

Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

Nov 13, 2025, 8:00 AM EST - 2 months ago

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

Nov 12, 2025, 3:30 PM EST - 2 months ago

MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential

Nov 10, 2025, 9:10 AM EST - 3 months ago

Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease

LLY

Nov 10, 2025, 7:00 AM EST - 3 months ago

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

Oct 7, 2025, 8:00 AM EDT - 4 months ago

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Sep 25, 2025, 3:48 AM EDT - 4 months ago

MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital

Aug 14, 2025, 8:00 AM EDT - 6 months ago

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

May 13, 2025, 4:30 PM EDT - 9 months ago

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025, 8:00 AM EDT - 9 months ago

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 9, 2025, 8:00 AM EDT - 9 months ago

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

Apr 29, 2025, 7:11 AM EDT - 10 months ago

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

Mar 25, 2025, 10:50 AM EDT - 11 months ago

MeiraGTx Holdings: Gaining Regulatory Focus

Mar 13, 2025, 9:51 AM EDT - 11 months ago

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars

Mar 13, 2025, 8:00 AM EDT - 11 months ago

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

Mar 13, 2025, 7:30 AM EDT - 11 months ago

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Feb 21, 2025, 6:30 AM EST - 1 year ago

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Jan 22, 2025, 4:09 PM EST - 1 year ago

MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value

Jan 22, 2025, 8:30 AM EST - 1 year ago

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Dec 3, 2024, 2:18 PM EST - 1 year ago

MeiraGTx Holdings: Behind The Recent Rally

Oct 15, 2024, 1:32 PM EDT - 1 year ago

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Oct 9, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Aug 12, 2024, 7:05 AM EDT - 1 year ago

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

Aug 12, 2024, 7:03 AM EDT - 1 year ago

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

Jul 15, 2024, 11:02 AM EDT - 1 year ago

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

May 9, 2024, 8:00 AM EDT - 1 year ago

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Apr 24, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx to Participate in Upcoming Investor Conferences

Apr 18, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

Mar 14, 2024, 8:30 AM EDT - 2 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

Feb 15, 2024, 8:23 AM EST - 2 years ago

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

Dec 21, 2023, 7:00 AM EST - 2 years ago

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

Nov 14, 2023, 8:00 AM EST - 2 years ago

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Oct 30, 2023, 8:28 AM EDT - 2 years ago

MeiraGTx shares jump as Sanofi invests in gene therapy

SNY

Oct 30, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Oct 24, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Aug 10, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Aug 1, 2023, 9:10 AM EDT - 2 years ago

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

Jul 19, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

Jun 27, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Jun 22, 2023, 4:01 PM EDT - 2 years ago

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,

May 11, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

May 3, 2023, 8:30 AM EDT - 3 years ago

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

Apr 21, 2023, 8:30 AM EDT - 3 years ago

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Mar 14, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

Dec 8, 2022, 4:30 PM EST - 3 years ago

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

Oct 4, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

Oct 1, 2022, 10:00 AM EDT - 3 years ago

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Sep 16, 2022, 2:00 AM EDT - 3 years ago

MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

Aug 11, 2022, 8:30 AM EDT - 3 years ago

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

CandleCloser Feb. 4 at 3:52 PM

$MGTX is a clinical-stage biotech (MeiraGTx) developing gene therapies for inherited diseases; its pipeline is promising but carries the high technical and regulatory risks of gene therapy.

1 · Reply

vu_jade Feb. 3 at 5:18 PM

$MGTX decent little news announcement today .. Chart turning more positive

0 · Reply

ErnieWorthing84 Feb. 3 at 5:17 PM

$MGTX Looks like they’re advancing the undisclosed dry AMD indication on Corp deck

0 · Reply

vu_jade Feb. 3 at 3:37 PM

$MGTX looking more Bullish here … needs some News

0 · Reply

DARKP00L Feb. 3 at 1:21 PM

0 · Reply

AimSmall Feb. 2 at 5:13 PM

$MGTX https://substack.com/@aimsmall/p-186344002

1 · Reply

slinghook67 Jan. 31 at 5:05 PM

1 · Reply

slinghook67 Jan. 30 at 3:13 AM

$MGTX This might as well have been written for MeiraGTx.... It's dead on. https://www.bain.com/insights/pharmaceuticals-m-and-a-report-2026/

1 · Reply

OptionsTag_902 Jan. 29 at 7:41 PM

$MGTX Quietly consolidating, watch for a breakout if volume confirms

0 · Reply

slinghook67 Jan. 29 at 12:17 PM

$MGTX Wow... an absolute MUST read.... https://www.statnews.com/2026/01/28/hologen-ai-biotech-startup-series-a-fundraise/

4 · Reply

vu_jade Jan. 29 at 3:20 AM

$MGTX back in accumulation zone …figure it wouldn’t bust that area of resistance .. maybe next time

0 · Reply

Bogy99 Jan. 27 at 9:18 PM

$MGTX no sign of shorts covering this month. New short data shows 5,705,628 shares short. That’s an increase 434,225 since end of December. This of course is a record high. With another dramatic increase in SI and a decrease in average daily volume. This can create a problem for these shorts if any positive news were to get announced. I personally hope they get they’re nutz roasted !! But that’s just me. Do you feel differently ??

0 · Reply

vu_jade Jan. 23 at 12:23 PM

$MGTX

1 · Reply

waterlock Jan. 23 at 3:25 AM

$MGTX should he interesting the following month

1 · Reply

vu_jade Jan. 22 at 3:55 PM

$MGTX $50 biotech masquerading at $8 now …

0 · Reply

ErnieWorthing84 Jan. 22 at 12:43 PM

$MGTX Make Zandy a billionaire

0 · Reply

vu_jade Jan. 21 at 8:42 PM

$MGTX $50 biotech languishing around $7.50 Loaded up

0 · Reply

Bogy99 Jan. 21 at 3:26 PM

$MGTX

2 · Reply

slinghook67 Jan. 20 at 7:42 PM

$MGTX Another example today of how incredibly undervalued Meira is with GSK's acquisition of RAPT Therapeutics. 10 months ago RAPT's market cap was ~$161M and they sold today for $2.2B. GSK wants their lead asset for food allergies which is in a mid Phase II non-pivotal trial with a follow-on Phase III required thereafter. The rest of their pipeline is thin as is their cash position and they do not have any manufacturing assets.

0 · Reply

SuperGreenToday Jan. 20 at 11:46 AM

$MGTX Share Price: $7.42 Contract Selected: Jul 17, 2026 $5 Calls Buy Zone: $2.39 – $2.95 Target Zone: $4.44 – $5.42 Potential Upside: 76% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

MGTX Jan. 18 at 8:27 PM

$MGTX $MGTX Why has Perceptive Advisors held since 2018 and just locked up for all of 2026? 🤔 1. They Own the Infrastructure: They financed the CDMO facilities. Even if a drug delays, the factory is a strategic asset for Big Pharma. 🏭 2. De-Risked Funding: The Hologen AI deal brought in ~$200M non-dilutive cash. No need to dump shares to fund the Parkinson's trial. 💰 3. Board Seat: Ellen Hukkelhoven (Perceptive) is on the Board. She sees the unblinded data. If it was bad, they wouldn't be locking up shares. 👩‍💼 • Sold a tiny slice for taxes 📉 • LOCKED UP ~10M shares for 12 months 🔒📈 Smart money isn't leaving before the Parkinson's data. They just confirmed their ticket for the 2026 ride. If they aren't selling, neither am I. 💎🙌

1 · Reply

slinghook67 Jan. 17 at 10:13 PM

$MGTX A great interview with the "legend" and MeiraGTX's largest shareholder. While he doesn't mention Meira specifically, he does say that Gene Therapy is the most undervalued area in all of Biotech today. Worth a listen..... https://open.spotify.com/episode/2kZpzMGWxYywlwZ9ttVoeW?si=vxGnOHVYT_KapvxXtkChQA&t=682&pi=CtWmyZy-RrSpW

3 · Reply

Market Cap	612.54M
Revenue (ttm)	33.28M
Net Income (ttm)	-147.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-444.08%
Debt to Equity Ratio	0.00

Volume	155,715
Avg Vol	507,274
Day's Range	N/A - N/A
Shares Out	80.49M
Stochastic %K	65%
Beta	1.38
Analysts	Strong Sell
Price Target	$26.75